Every Tuesday we send out the MedComms Networking email newsletter to subscribers. It includes brief commentary on what we're doing and planning, and highlights relevant news to encourage sharing of information, experiences and ideas and to stimulate discussion. The text and links included below, by definition, were accurate on the day of publication, but may then become outdated.
MedComms Networking - 14 November 2023
Yesterday, EPG Health published The Future of HCP Engagement Impact. A 73-page report from a multi-stakeholder study of the current challenges, views and behaviours of HCPs, pharma and their service providers. Interestingly, they conclude that "...pharma often lacks sufficient focus on the content and channels that HCPs value, and finds it difficult to measure meaningful outcomes and impact. Furthermore, signs of a back-to-normal mentality post-pandemic and persistent short-term thinking threaten to undermine the effectiveness of future activity."
In tomorrow's #MedComms webinar, we'll discuss their data. Please join us.
Heck, it's almost like I plan some of this. At least, sometimes!
I love that anyone can access the #MedComms webinars live, or the recordings afterwards at NetworkPharma.tv. Anytime. Entirely free of charge. We've covered many topics, heard insights from many experts and, I'm sure, catalysed many discussions and arguments.
I'm continually reminded, though, of the gulf between those who can access knowledge and those who can't. It seems to me, that gulf is widening rapidly between those who are on the inside working with generative AI and those who aren't.
In January it was fun to run a webinar about something new called ChatGPT. There was no planning at all! Should we take notice of ChatGPT and allied AI technologies in MedComms? featured Martin Delahunty (Inspiring STEM Consulting), Katja Martin (medtextpert), Stephen Mott (PharmAdvisor) and Avishek Pal (Novartis). In just 10 days, nearly (but not quite!) 1,000 people registered. A #MedComms webinar record I'm unlikely to match. We had little idea about what we were talking about. Our key message was simply; "everyone should have a play".
Now, AI is discussed everywhere - but often behind closed doors. Or at least at a price.
In last week's #MedComms webinar, The Ultimate Guide to Digital Engagement in Pharma - Top Tips, panellist Faisal Ahmed mentioned using Microsoft's new Copilot. Co-panellist Tim Sparke pointed out most of us don't have access yet and won't for some time!
In last week's ISMPP U webinar to announce the launch of their AI Position Statement and Call to Action (the recording is behind a paywall unless you are a member), panellists referred to the many experiments that are being run within their (very large) MedComms organisations but, understandably, didn't provide any detail.
Yesterday, in pharmaphorum's webinar, which anyone can now watch, Harnessing Omnichannel, AI, and beyond: Reimagining Scientific Publications, panellists knowingly referred to how much experimentation is happening within companies. Again, little detail.
I'm involved in a couple of meetings later this week, talking to specialist Freelancers about what's changing in MedComms. I'm curious. How are they keeping up? One freelancer I talked to yesterday is thinking about re-joining a company to up-skill. How else could they do it, from the outside?
I still worry about who isn't even playing yet.
Stay well, everyone.
P.S. Next week we'll hear about how Avalere Health, formerly Fishawack Health, is being purpose built to meet the future challenges of Medical Affairs and the teams they work with. Join us.
Managing Director, NetworkPharma Ltd
Follow me on LinkedIn @NetworkPharma
Join more than 8,000 international colleagues in the MedComms Networking Linkedin Group
The information at MedCommsNetworking.com is always bang up-to-date!